1. Home
  2. UFI vs ANVS Comparison

UFI vs ANVS Comparison

Compare UFI & ANVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Unifi Inc. New

UFI

Unifi Inc. New

HOLD

Current Price

$6.69

Market Cap

76.4M

ML Signal

HOLD

Logo Annovis Bio Inc.

ANVS

Annovis Bio Inc.

HOLD

Current Price

$1.30

Market Cap

55.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
UFI
ANVS
Founded
1969
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Textiles
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
76.4M
55.9M
IPO Year
1994
2019

Fundamental Metrics

Financial Performance
Metric
UFI
ANVS
Price
$6.69
$1.30
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $13.50
AVG Volume (30 Days)
53.1K
★ 1.3M
Earning Date
05-05-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 39.39
EPS
N/A
★ N/A
Revenue
★ $531,303,000.00
N/A
Revenue This Year
$1.39
N/A
Revenue Next Year
$12.57
N/A
P/E Ratio
★ N/A
N/A
Revenue Growth
N/A
★ N/A
52 Week Low
$2.96
$1.04
52 Week High
$8.47
$5.50

Technical Indicators

Market Signals
Indicator
UFI
ANVS
Relative Strength Index (RSI) 46.53 46.55
Support Level $6.42 $1.04
Resistance Level $6.76 $2.43
Average True Range (ATR) 0.23 0.09
MACD -0.02 0.04
Stochastic Oscillator 57.45 78.21

Price Performance

Historical Comparison
UFI
ANVS

About UFI Unifi Inc. New

Unifi Inc is a multi-national company. It manufactures and sells synthetic and recycled products made from polyester and nylon predominantly to other yarn manufacturers and knitters and weavers that produce fabric for apparel, hosiery, home furnishings, automotive, industrial, and other end-use markets. Polyester yarns include partially oriented yarn (POY), textured, solution and package dyed, twisted, beamed, and draw wound yarns, and each is available in virgin or recycled varieties. UNIFI offers specialized yarns, premium value-added (PVA) yarns, and commodity yarns. The company's reportable segments are; the Americas, Brazil, and Asia. Its maximum revenue is derived from the Americas.

About ANVS Annovis Bio Inc.

Annovis Bio Inc, a clinical stage drug platform company, develops drugs to treat neurodegeneration in the United States. The company's flagship candidate, buntanetap, is in clinical trials for the treatment of Alzheimer's disease, Parkinson's disease, and Lewy body dementia. It also develops ANVS405, which is in phase 2 and 3 clinical trials for the treatment of traumatic brain injury and/or stroke; and ANVS301, which finished phase 1 clinical trial developed to increase cognitive capability in later stages of alzheimer's disease and dementia.

Share on Social Networks: